Review articles and clinical analyses in Immunology
The first randomized head-to-head trial finds rituximab noninferior to IV ocrelizumab for MRI disease control in newly diagnosed relapsing MS — at roughly one-sixth the price. Where each anti-CD20 antibody…
The EU approved tolebrutinib (Cenrifki) as the first drug to slow disability in non-relapsing secondary progressive MS while the FDA rejected it over severe liver injury — a look at…
More than a dozen disease-modifying therapies, five mechanistic classes, and few head-to-head trials. A structured framework for choosing in MS: efficacy tiers and the limits of cross-trial comparison, the differences…
